Crossmark Global Holdings Inc. Raises Stock Holdings in Becton, Dickinson and Company $BDX

Crossmark Global Holdings Inc. grew its stake in Becton, Dickinson and Company (NYSE:BDX) by 74.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,356 shares of the medical instruments supplier’s stock after buying an additional 7,002 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Becton, Dickinson and Company were worth $3,174,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Ethic Inc. increased its position in Becton, Dickinson and Company by 9.5% in the fourth quarter. Ethic Inc. now owns 40,970 shares of the medical instruments supplier’s stock worth $7,951,000 after buying an additional 3,568 shares in the last quarter. Strengthening Families & Communities LLC increased its position in Becton, Dickinson and Company by 2.4% in the fourth quarter. Strengthening Families & Communities LLC now owns 14,583 shares of the medical instruments supplier’s stock worth $2,830,000 after buying an additional 339 shares in the last quarter. Violich Capital Management Inc. increased its position in Becton, Dickinson and Company by 2.3% in the fourth quarter. Violich Capital Management Inc. now owns 20,286 shares of the medical instruments supplier’s stock worth $3,937,000 after buying an additional 461 shares in the last quarter. Generali Asset Management SPA SGR increased its position in Becton, Dickinson and Company by 1.1% in the fourth quarter. Generali Asset Management SPA SGR now owns 11,483 shares of the medical instruments supplier’s stock worth $2,229,000 after buying an additional 128 shares in the last quarter. Finally, FSB Premier Wealth Management Inc. increased its position in Becton, Dickinson and Company by 42.1% in the fourth quarter. FSB Premier Wealth Management Inc. now owns 11,276 shares of the medical instruments supplier’s stock worth $2,188,000 after buying an additional 3,341 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the company. Piper Sandler reduced their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Argus cut their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research report on Monday, March 23rd. The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a research report on Friday, April 10th. They set a “neutral” rating and a $167.00 target price for the company. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Finally, TD Cowen cut their target price on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research report on Monday, May 4th. Seven analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average target price of $184.86.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the transaction, the director owned 36,763 shares in the company, valued at $6,713,291.43. This trade represents a 2.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last three months, insiders sold 1,102 shares of company stock worth $198,909. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $143.11 on Tuesday. The stock has a market capitalization of $39.43 billion, a PE ratio of 36.23, a P/E/G ratio of 10.60 and a beta of 0.22. The business has a 50 day simple moving average of $157.19 and a two-hundred day simple moving average of $180.46. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts predict that Becton, Dickinson and Company will post 12.59 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.9%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Becton, Dickinson and Company announced that its board has initiated a stock repurchase plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.